{"id":198555,"name":"BIODESIX, INC.","slug":"biodesix-inc","state":"CO","country":"United States of America","description":"Fully integrated molecular diagnostic company.","totalSpending":1020000,"filings":34,"yearlySpending":[{"year":2018,"income":120000},{"year":2019,"income":120000},{"year":2020,"income":120000},{"year":2021,"income":150000},{"year":2022,"income":120000},{"year":2023,"income":120000},{"year":2024,"income":150000},{"year":2025,"income":120000}],"issues":["MMM","MED","HCR"],"firms":["TODD STRATEGY GROUP"],"lobbyists":["DANIEL TODD","PAUL EDATTEL","JEFF LUCAS","TAYLOR SEXTON","NICHOLAS UEHLECKE","ERIC BERGREN","KATHERINE COTTON","TED LEHMAN","KIMBERLY LINTHICUM"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)","Food & Drug Administration (FDA)"],"sampleDescriptions":["Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.\nImplementation of changes to Medicare payments for clinical laboratory tests.\nMedicare treatment of outpatient reimb","FDA regulation of laboratory developed tests.","FDA regulation of laboratory developed tests.","Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.\nImplementation of changes to Medicare payments for clinical laboratory tests.\nMedicare treatment of outpatient reimb","FDA regulation of laboratory developed tests."],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}